KLK3 and prostate cancer: A difference in PSA (p = 0.006) was observed upon prostate cancer outcome (i.e., cases vs. controls), which the prostate cancer cases indicated a higher PSA (25.98 ± 20.77 ng/mL), while a lower PSA (8.28 ± 3.61 ng/mL) was observed in non-prostate cancer controls.